Clinical trial · Interventional
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-CA, to improve the quality of life and cognitive function in Service Members, Veterans and civilians who are survivors of brain cancer or a brain tumor (CA participants). This study will also assess the ability of the HOBSCOTCH-CA program to improve quality of life in caregivers of patients with brain cancer/tumor and to reduce caregiver burden. Enrolling with a Caregiver is optional for CA participants. Investigators will compare two groups of CA participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOCTCH-CA immediately (Group 1) and another group that will receive HOBSCOTCH-CA (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total. HOBSCOTCH-CA involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a "pre" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. CA participants are asked to do short homework assignments and keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Cognitive Dysfunction | — | UNRESOLVED | — |
| Low Grade Astrocytoma | Low Grade Astrocytoma | ONTOLOGY_EXACT | 0.90 |
| Low-grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
| Memory Disorders | — | UNRESOLVED | — |
| Memory Dysfunction | — | UNRESOLVED | — |
| Memory Impairment |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HOBSCOTCH-CA | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- CA Participant-Group 1
- description
- After enrollment and completion of baseline assessments, CA Participant Group 1 will receive the HOBSCOTCH-PTE intervention consisting of 1:1 sessions delivered once per week including: * 1 pre-HOBSCOTCH Session (on webcam) * 1 educational session (on webcam) * 6 telephone sessions (option to do on webcam) * 1 wrap-up session (webcam or telephone)
- interventionNames
- Behavioral: HOBSCOTCH-CA
- type
- ACTIVE_COMPARATOR
- label
- CA Participant-Group 2
- description
- After a 3-month waiting period and having completed baseline and 3-month study assessments, CA Participant Group 2 will receive the HOBSCOTCH-CA intervention consisting of 1:1 sessions delivered once per week including: * 1 pre-HOBSCOTCH Session (on webcam) * 1 educational session (on webcam) * 6 telephone sessions (option to do on webcam) * 1 wrap-up session (webcam or telephone)
- interventionNames
- Behavioral: HOBSCOTCH-CA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion/exclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1. - 3. will be confirmed by referring providers. Participants who learn about the study here and elsewhere will be instructed on how to confirm their eligibility with their provider. Inclusion Criteria for CA Participant: 1. 18 + years 2. Service members, Veterans and civilians with a diagnosis of brain cancer (excluding glioblastoma) 3. Diagnosis of primary brain tumor with expected survival of 2 years or greater (e.g., low-grade glioma, oligodendroglioma, IDH mutant astrocytoma, meningioma) defined as the presence of a primary lesion on neuroimaging (CT or MRI), confirmed by histopathological examination (Note: some patients being treated for meningioma may be treated with radiotherapy without need for initial histopathologic confirmation) 4. Patients undergoing surgical and/or radiation therapy will have completed their treatment at least 3 months prior to being enrolled in trial (Note: patients receiving chemotherapy or other systemic therapy will be included) 5. Stable on all CNS acting medications for one month prior to enrollment 6. Subjective cognitive complaints 7. Literate and proficient in English 8. Internet access for the pre-session and Session 1 of the HOBSCOTCH-CA program; telephone access for sessions 2-8 Exclusion Criteria for CA Participant: 1. Presence of a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease) 2. Acute psychiatric disorder or substance abuse 3. Patients with glioblastoma (GBM) Inclusion Criteria for CA Participant Caregiver: 1. Age 18 + 2. Caregiver to a patient with a confirmed diagnosis of brain cancer/tumor survivor 3. CA Subject has given permission for their caregiver to participate 4. Literate and proficient in English 5. Internet access (for Pre-HOBSCOTCH and Session 1) 6. Telephone access (for Session 8) Exclusion Criteria for CA Participant Caregiver: 1. Significant visual impairment precluding reading or writing 2. No reliable telephone or internet access
References
Publications (0)
Data not yet available